The DOI matches its Crossref record.
The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound
Open accessAbstract
CD22 is a B cell–specific transmembrane protein of the Siglec family. It binds specifically to α2,6-linked sialic acid (Sia) residues, which are also present on glycoproteins on the B cell surface. CD22 acts as a negative regulator in B cell receptor–mediated signaling by recruitment of Src homology 2 domain–containing tyrosine phosphatase (SHP)-1 to its intracellular tail. To analyze how ligand-binding of CD22 influences its intracellular signaling domain, we designed synthetic sialosides as inhibitors for the lectin domain of CD22. One of these compounds inhibited binding of human CD22-Fc to target cells over 200-fold better than Sia and was highly selective for human CD22. When Daudi cells or primary B cells were stimulated with anti-immunoglobulin (Ig)M in presence of this sialoside inhibitor, a higher Ca2+ response was observed, similar to CD22-deficient B cells. Accordingly, a lower tyrosine-phosphorylation of CD22 and SHP-1 recruitment was demonstrated in presence of the sialoside. Thus, by interfering with ligand binding of CD22 on the B cell surface, we have shown for the first time that the lectin domain of CD22 has a direct, positive influence on its intracellular inhibitory domain. Also, we have developed a novel low molecular weight compound which can enhance the response of human B cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. (2007) · Nature Reviews Immunology · doi:10.1038/nri2056 · Cited by 2,031
B cell antigen receptor signaling 101
DALPORTO, J. (2004) · Molecular Immunology · doi:10.1016/j.molimm.2004.04.008 · Cited by 537
Siglecs—the major subfamily of I-type lectins
Varki, A., & Angata, T. (2006) · Glycobiology · doi:10.1093/glycob/cwj008 · Cited by 518
Brewer, C. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00364-0 · Cited by 435
Pillai, S., Netravali, I. A., Cariappa, A., & Mattoo, H. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075018 · Cited by 357
Metadata
- Authors
- Kelm, S., Gerlach, J., Brossmer, R., Danzer, C.-P., & Nitschke, L.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2002-04-29
- Volume
- 195
- Issue
- 9
- Pages
- 1207-1213
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2148050927
- Cited by
- 179
- References
- 0
- FWCI
- 5.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound. https://app.cochat.ai/papers/10.1084/jem.20011783
- The paper
- Kelm, S., Gerlach, J., Brossmer, R., Danzer, C.-P., & Nitschke, L. (2002). The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor Compound. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20011783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.